XLO icon

Xilio Therapeutics

0.7000 USD
-0.0001
0.01%
At close Aug 26, 4:00 PM EDT
After hours
0.6860
-0.0140
2.00%
1 day
-0.01%
5 days
3.40%
1 month
2.64%
3 months
-20.35%
6 months
-28.39%
Year to date
-34.58%
1 year
-23.43%
5 years
-95.63%
10 years
-95.63%
 

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Employees: 73

0
Funds holding %
of 7,433 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2.39% more ownership

Funds ownership: 43.52% [Q1] → 45.9% (+2.39%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

1% less capital invested

Capital invested by funds: $16.3M [Q1] → $16.2M (-$157K) [Q2]

3% less funds holding

Funds holding: 35 [Q1] → 34 (-1) [Q2]

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$2
186%
upside
Avg. target
$2
186%
upside
High target
$2
186%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Leerink Partners
Daina Graybosch
186%upside
$2
Outperform
Initiated
6 Aug 2025

Financial journalist opinion

Based on 3 articles about XLO published over the past 30 days

Negative
Zacks Investment Research
1 week ago
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.24 per share a year ago.
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 week ago
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
3 weeks ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective August 1, 2025, the company granted non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 month ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non-qualified stock options to purchase 10,700 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
2 months ago
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors.
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Neutral
GlobeNewsWire
2 months ago
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutive capital received, under certain circumstances Financing co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and other new and existing investors WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the closing of its previously announced underwritten public offering of pre-funded warrants and accompanying common stock warrants for initial gross proceeds of approximately $50.0 million before deducting underwriting discounts and commissions and offering expenses.
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
Neutral
GlobeNewsWire
2 months ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective June 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
2 months ago
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten public offering of pre-funded warrants to purchase 66,676,000 shares of common stock (the “pre-funded warrants”), accompanied by Series A warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series A warrants”), Series B warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series B warrants”) and Series C warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series C warrants”). The combined public offering price of one pre-funded warrant, one Series A warrant, one Series B warrant and one Series C warrant, which are being sold together but are immediately separable, is $0.7499, which is equal to the combined offering price of the pre-funded warrants, Series A warrants, Series B warrants and Series C warrants, less the $0.0001 per share exercise price of the pre-funded warrants. The offering is expected to close on or about June 5, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Xilio.
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Neutral
GlobeNewsWire
2 months ago
Xilio Therapeutics Announces Proposed Public Offering
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants), Series B warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants) and Series C warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants). All of the securities to be sold in the proposed offering will be offered by Xilio. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Xilio Therapeutics Announces Proposed Public Offering
Neutral
GlobeNewsWire
2 months ago
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
Charts implemented using Lightweight Charts™